Internal Medicine, Hematology & Oncology · Flint, MI
NPI
1477518629
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
302 Kensington Ave
Flint, MI, 48503
Phone (810) 762-8200
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.6M
109,285 services
Medicare patients, 2024
478
Average age 72
Drug cost, 2024
$4.6M
1,952 prescriptions
Company payments, 2025
$1,641
From 36 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Khalil A Katato was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 40,800 times for 63 patients. In total Khalil A Katato billed 109,285 services in 110 codes, and Medicare paid $1.6M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-04-15.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 40,800 | 63 | $0.27 | $11K |
| J0897 Injection, denosumab, 1 mg | Office | 2,760 | 18 | $20.49 | $57K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 875 | 35 | $0.09 | $78.68 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 845 | 12 | $6.41 | $5,419 |
| 85025 Blood Count | Office | 812 | 305 | $7.56 | $6,136 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 650 | 23 | $0.66 | $426 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 370 | 13 | $0.25 | $93.88 |
| 99213 Office E&M - Established | Office | 287 | 170 | $59.83 | $17K |
| Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Office | 276 | 15 | $111.53 | $31K |
| 96372 Injection Administration | Office | 255 | 71 | $10.52 | $2,684 |
| 99214 Office E&M - Established | Office | 168 | 79 | $88.35 | $15K |
| 96367 Intravenous Infusion, Hydration | Office | 160 | 38 | $20.66 | $3,306 |
| 96413 Chemotherapy Administration | Office | 145 | 48 | $92.48 | $13K |
| 96375 Injection Administration | Office | 137 | 38 | $11.20 | $1,534 |
| 96365 Intravenous Infusion, Hydration | Office | 124 | 73 | $44.63 | $5,535 |
By year: 2022 $1.7M for 118,256 services; 2023 $1.0M for 66,275 services; 2024 $1.6M for 109,285 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 812 | 305 | $7.56 | $6,136 |
Medicare prescription drug claims, 2024
In 2024, the drug Khalil A Katato prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 171 prescriptions and refills. In total Khalil A Katato wrote 1,952 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 171 | 171 | 51 | $3,084 |
| Letrozole Generic | 96 | 258 | 28 | $5,494 |
| Anastrozole Generic | 84 | 186 | 24 | $3,262 |
| Prochlorperazine Maleate Generic | 74 | 74 | 38 | $1,251 |
| Prednisone Generic | 71 | 95 | 20 | $359 |
| Morphine Sulfate Er Morphine Sulfate | 63 | 63 | 17 | $1,610 |
| Xarelto Rivaroxaban | 63 | 129 | 15 | $67K |
| Dexamethasone Generic | 59 | 67 | 17 | $1,149 |
| Alprazolam Generic | 51 | 51 | 12 | $192 |
| Fentanyl Generic | 51 | 51 | 11 | $4,969 |
| Oxycodone Hcl Generic | 50 | 50 | 12 | $644 |
| Xtandi Enzalutamide | 47 | 47 | Under 11 | $622K |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 46 | 46 | 34 | $463 |
| Gabapentin Generic | 40 | 50 | Under 11 | $745 |
| Exemestane Generic | 39 | 89 | 11 | $7,493 |
Brand drugs: - claims; generic drugs: 1,562 claims; opioid claims: 382.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Khalil A Katato $1,641 ($1,641 in general payments such as food, travel and fees) from 36 companies. The largest payer was Novartis Pharmaceuticals Corporation with $209.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 16 | $209 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 2 | $121 |
| Genentech USA, Inc. ROG.SW | 4 | $108 |
| GlaxoSmithKline, LLC. GSK | 5 | $90.76 |
| Merck Sharp & Dohme LLC MRK | 3 | $74.5 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $70.1 |
| Janssen Biotech, Inc. JNJ | 3 | $65.16 |
| Aveo Pharmaceuticals, Inc. | 3 | $60 |
| Incyte Corporation INCY | 3 | $57.82 |
| Deciphera Pharmaceuticals Inc. | 3 | $53.34 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.